Astrazeneca

FromAstraZeneca ([email protected])
Subject (131)Imfinzi-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
Preheader (131)Imfinzi-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
Typography
Arial
Colors
Text Analysis
Body Words143
Subject Words21
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px770 px
X-Spam Score1.0
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeEvening

Imfinzi-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

Imfinzi-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
Imfinzi-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial